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Abstract:	  
A	  novel	  vaccine	  development	  platform	  that	  enables	   the	  site-­‐specific	  conjugation	  of	  
synthetic	   lipid	   adjuvants	   to	   recombinant	   proteins	   was	   produced.	   This	   technology	  
facilitates	   the	   simple	   and	   efficient	   production	   of	   homogeneous,	   chemically-­‐defined,	  
semisynthetic	   lipoprotein	   vaccines.	   Using	   a	   polytope	   ‘string-­‐of-­‐beads’	   approach,	   a	  
synthetic	   gene	   incorporating	   seven	   Streptococcus	   pyogenes	   M	   protein	   strain-­‐specific	  
antigens,	   and	   a	   conserved	   M	   protein	   antigen	   (J14)	   was	   produced,	   expressed,	   and	  
attached	  to	  a	  lipoamino	  acid	  based	  adjuvant	  (lipid	  core	  peptide;	  LCP).	  Nanoparticles	  (40	  
nm	   diameter)	   of	   an	   optimal	   size	   for	   stimulating	   antibody-­‐mediated	   immunity	   were	  
formed	   upon	   the	   addition	   of	   these	   lipoproteins	   to	   aqueous	   buffer	   (PBS).	   Systemic	  
antigen-­‐specific	  IgG	  antibodies	  were	  raised	  against	  all	  eight	  antigens	  in	  C57BL/6J	  mice,	  
without	   the	   need	   to	   formulate	  with	   additional	   adjuvant.	   These	   antibodies	   bound	   cell	  
surface	   M	   proteins	   of	   S.	   pyogenes	   strains	   represented	   within	   the	   polytope	   sequence,	  
with	  higher	  antibody	  levels	  observed	  where	  a	  dendritic	  cell	  targeting	  peptide	  (DCpep)	  
was	  incorporated	  within	  the	  LCP	  adjuvant.	  
	  





Immunization	   with	   attenuated	   microorganisms	   has	   proven	   to	   be	   one	   of	   the	   most	  
effective	  means	   to	  prevent	  disease.1	  Despite	   this	  success,	  many	  diseases	   lack	  effective	  
vaccines	   (e.g.	   rheumatic	   heart	   disease	   (RHD),	   malaria,	   and	   tuberculosis),2	   in	   part	  
because	   of	   significant	   risks	   associated	   with	   this	   approach	   (e.g.	   infectivity	   in	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immunocompromized	   individuals).	   This	   has	   lead	   to	   a	   shift	   towards	   subunit	   vaccines,	  
which	   contain	   only	   the	  minimal	   components	   required	   to	   elicit	   protective	   immunity.1	  
While	   this	   approach	   enhances	   vaccine	   safety,	   the	   capacity	   to	   elicit	   potent	   immune	  
responses	   is	   significantly	   reduced,	   requiring	   their	   administration	   with	   powerful	  
immunostimulatory	  compounds	  known	  as	  adjuvants.	  	  
	  
A	   variety	   of	   molecules	   (lipids,	   glycolipids,	   nucleotides,	   and	   flagellin)	   have	   been	  
investigated	   as	   adjuvants	   for	   subunit	   vaccines.3	   Our	   work	   has	   focused	   on	   synthetic	  
lipoamino	  acids4	  (α-­‐amino	  acids	  with	  variable	   length	  alkyl	  side-­‐chains;	  Figure	  1,	  A)	  as	  
an	  alternative	  to	  bacterial	  or	  synthetic	  lipopeptide	  adjuvants	  (e.g.	  Pam2-­‐	  and	  Pam3Cys)	  
for	  peptide-­‐based	  vaccines,	  due	  to	  their	  simple,	  inexpensive	  synthesis,	  and	  ability	  to	  be	  
incorporated	   using	   standard	   peptide	   coupling	   protocols.	   The	   attachment	   of	   2-­‐3	  
lipoamino	  acids,	  with	  optimized	  side-­‐chain	   length	  and	  spacing	   (e.g.	  Figure	  1,	  A;	   called	  
lipid	  core	  peptides	  (LCPs)),	  has	  been	  demonstrated	  to	  provide	  adjuvant	  activity	  towards	  
a	   variety	   of	   peptide	   antigens,5	   leading	   to	   antibody-­‐mediated	   (mucosal	   and	   systemic)6	  
and	  cellular	  immunity7	  following	  parenteral	  or	  mucosal	  administration.8	  This	  adjuvant	  
activity	   at	   least	   partially	   involves	   signaling	   through	   Toll-­‐like	   receptor	   2	   (TLR2),9	  
through	  which	  bacterial	  lipopeptides	  also	  signal.3	  
	  
In	   order	   to	   develop	   the	   aforementioned	   lipopeptide	   vaccines,	   protective	   peptide	  
epitopes	  must	  be	  mapped	  for	  the	  disease	  of	  interest.10	  In	  many	  cases	  this	  information	  is	  
not	  available,	  or	  mapping	  experiments	  have	  failed	  to	  define	  linear	  protective	  epitopes,	  
necessitating	   a	   whole	   protein	   approach.	   In	   addition,	   the	   ability	   to	   produce	   large	  
amounts	   of	   synthetic	   homogeneous	   peptides,	   in	   high	   yield,	   rapidly	   decreases	   with	  
increasing	  peptide	  length.11	  As	  a	  consequence,	  peptide	  vaccines	  can	  only	  incorporate	  a	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few	  epitopes,	  reducing	  their	  capacity	  to	  protect	  whole	  populations	  against	   infection.	  A	  
recombinant	   protein	   approach	   would	   overcome	   these	   difficulties,	   as	   proteins	   can	   be	  
expressed	  on	  an	  industrial	  scale,	  with	  excellent	  batch-­‐to-­‐batch	  reproducibility,	  at	  lower	  
cost	   than	   synthetic	   peptides,12	   and	  may	   incorporate	   a	   large	  number	   of	   antigens,	  with	  
correct	  presentation	  of	  folded	  epitopes.	  	  
	  
Based	   on	   this	   knowledge,	  we	   sought	   to	   develop	   techniques	   to	   produce	   semisynthetic	  
LCP	  vaccines	   incorporating	  recombinant	  protein	  antigens	  (Figure	  1,	  A).	  This	  approach	  
allows	   the	   incorporation	   of	   non-­‐natural	   components,	   linkages,	   and	   attachment	  
configurations	   (e.g.	   branching),	   which	   could	   not	   be	   achieved	   with	   a	   recombinant	  
approach	  alone,	  while	  generating	  a	  product	  that	  can	  be	  characterized	  at	  the	  molecular	  
level.	   Further,	   the	   products	   of	   this	   approach	   crosslink	   antigen	   and	   adjuvant	   into	   the	  
same	  molecule,	  ensuring	  their	  co-­‐delivery	  to	  cells	  of	   the	   immune	  system,	  an	  approach	  
that	   in	   many	   cases	   significantly	   enhances	   the	   immune	   response	   towards	   attached	  
antigens.13	  Maleimide	  conjugation	  was	  selected	   for	   this	  purpose	  as	  maleimides	  can	  be	  
readily	   incorporated	   into	   our	   lipid	   adjuvants,	   are	   inexpensive	   to	   synthesize,14	   and	  
enable	  simple,	  one-­‐step	  conjugation	  reactions.	  Maleimides	  react	  specifically	  with	  thiols	  
at	  neutral	  pH,	  generating	  a	  stable	  thioether	  linkage	  (Figure	  1,	  A).15	  To	  participate	  in	  this	  
reaction,	   the	   recombinant	   protein	   requires	   the	   presence	   of	   a	   single	   cysteine	   residue,	  
which	  can	  be	  readily	  incorporated	  using	  site-­‐directed	  mutagenesis.	  
	  
Group	  A	  Streptococcus	  (GAS;	  Streptococcus	  pyogenes),	  which	  is	  associated	  with	  diseases	  
including	   pharyngitis	   (sore	   throat)	   and	  RHD,16	  was	   selected	   as	   a	  model	   organism	   for	  
developing	  this	  platform.	  As	  over	  200	  strains	  have	  been	  identified,	  the	  development	  of	  a	  
broadly	  protective	  vaccine	  requires	  the	  incorporation	  of	  multiple	  protective	  antigens,16	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favoring	  a	  recombinant	  approach.	  Further,	  many	  well-­‐defined	  protective	  GAS	  antigens	  
have	   been	   reported,17-­‐20	   providing	   valuable	   knowledge	   for	   antigen	   selection.	   For	   this	  
work,	   peptide	   antigens	   from	   the	   GAS	   cell-­‐surface	   M	   protein,	   which	   are	   amongst	   the	  
most	   promising	   GAS	   vaccine	   targets,16	   were	   selected.	   A	   ‘string-­‐of-­‐beads’	   (polytope)	  
approach	  was	  used	   (1,	   Figure	  2,	  A)	   to	   link	   seven	   strain-­‐specific	  N-­‐terminal	  M	  protein	  
antigens,	   from	   GAS	   isolates	   prevalent	   in	   the	   Australian	   Aboriginal	   population	   of	   the	  
Northern	  Territory,18	  to	  a	  conserved	  M	  protein	  conformational	  B	  cell	  epitope	  (J14i;	  bold	  
sequence	  in	  J14),	  which	  is	  flanked	  by	  peptides	  designed	  to	  promote	  its	  native	  α-­‐helical	  
structure	   (J14:	  KQAEDKVKASREAKKQVEKALEQLEDKVK).17	   Several	  of	   these	  antigens,	  
when	  administered	  as	  part	  of	  a	  synthetic	  LCP	  system,	  have	  been	  demonstrated	  to	  elicit	  
long-­‐lasting	   antibody	  mediated	   immunity	   in	  murine	   preclinical	  models.21	   A	   universal	  
source	   of	   T	   cell	   help	   (PADRE	   1024.03)22	   was	   also	   included	   to	   aid	   memory	   B	   cell	  
production	   in	   genetically	   diverse	   populations	   (e.g.	   humans),	   along	   with	   a	   C-­‐terminal	  
cysteine	  to	  allow	  site-­‐specific	  conjugation	  to	  the	  lipid	  adjuvant.	  	  
	  
The	   lipid	   adjuvants	   used	   in	   this	  work	   (2	   and	  3;	   Figure	   1,	  A)	   feature	   three	   lipoamino	  
acids	  (2-­‐aminohexadecanoic	  acid),	  a	  short	  peptide	  to	  enhance	  solubility	  under	  aqueous	  
conditions,	  and	  an	  N-­‐terminal	  maleimide	  for	  bioconjugation	  to	  1.	  As	  dendritic	  cell	  (DC)	  
targeting	   can	   enhance	   antibody-­‐mediated	   immunity,	   and	   significantly	   reduce	   the	  
amount	  of	  antigen	  required	  to	  ensure	  effective	  immunity,23	  we	  decided	  to	  incorporate	  a	  
DC	  targeting	  peptide	  (DCpep;24	  Figure	  1,	  A)	  into	  adjuvant	  2.	  An	  additional	  adjuvant	  (3),	  
incorporating	   a	   peptide	  without	   DC	   targeting	   potential	   (CONTROLpep;24	   Figure	   1,	  A)	  
was	  also	  produced	  as	  a	  control.	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Herein	   we	   describe	   the	   processes	   used	   to	   develop	   and	   optimize	   our	   polytope	   GAS	  
antigen	  1	   (Figure	   2),	   synthetic	   lipid	   adjuvants	   (2,	  3;	   Figure	   1,	  A),	   and	   bioconjugation	  
conditions,	   to	   enable	   the	   simple,	   high	   yielding	   production	   of	   semisynthetic	   lipid-­‐
adjuvanted	  nanoparticulate	  vaccines.	  The	  vaccines	  were	  produced	  with	  (6)	  or	  without	  
(7)	  a	  DC	  targeting	  sequence,	  enabling	  the	  effect	  of	  this	  modification	  on	  antibody-­‐levels	  
to	   be	   assessed	   using	   a	   murine	   preclinical	   model.	   Extensive	   characterization	   of	   the	  
vaccines	   was	   undertaken	   to	   confirm	   particle	   size,	   purity,	   lack	   of	   endotoxin	  
contamination,	   and	   site-­‐specific	   bioconjugation.	   As	   an	   indicator	   of	   the	   protective	  
potential	   of	   these	   vaccines,	   antisera	   from	   subcutaneously	   immunized	   mice	   were	  
evaluated	  for	  their	  potential	  to	  bind	  cell	  surface	  M	  proteins	  from	  a	  panel	  of	  GAS	  strains	  




Detailed	  methods,	  sequences,	  and	  characterization	  data	  are	  provided	  as	  supplementary	  
information	  (available	  online	  at	  http://www.nanomedjournal.com).	  
	  
Recombinant	  protein	  antigen	  
	  
Recombinant	  protein	  antigen	  1	  (Figure	  2,	  A;	  Table	  S1)	  was	  designed,	  reverse-­‐translated,	  
and	   codon	   optimized	   for	   expression	   in	   Escherichia	   coli.	   The	   gene	   (Table	   S2)	   was	  
assembled	   from	   18	   overlapping	   oligonucleotides	   (Table	   S3)	   by	   PCR-­‐based	   gene	  
synthesis,25	  inserted	  into	  pTXB1,	  and	  mutated	  to	  generate	  a	  C-­‐terminal	  cysteine	  fusion.	  
The	   protein	   was	   expressed	   in	   BL21(DE3)-­‐RIL	   (37	   °C,	   4	   hours),	   with	   0.5	   mM	  
isopropylthio-­‐β-­‐galactoside	  (IPTG)	  induction	  at	  OD600	  0.6,	  and	  purified	  to	  homogeneity	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(Figure	  2,	  C-­‐E)	  by	  reversed-­‐phase	  high-­‐performance	  liquid	  chromatography	  (RP-­‐HPLC)	  
after	   denaturing	   lysis	   and	   enrichment	   by	   nickel-­‐nitrilotriacetic	   acid	   (Ni-­‐NTA)	  
chromatography.	  
	  
Lipid	  adjuvant	  peptide	  synthesis	  
	  
Lipid	   adjuvant	   peptides	   2	   and	   3	   (Figure	   1,	   A)	   were	   synthesized	   using	   microwave-­‐
assisted	   Fmoc	   (9-­‐fluorenylmethyloxycarbonyl)	   solid-­‐phase	   peptide	   synthesis	   (SPPS).	  
The	   lipid	   adjuvant	   was	   incorporated	   using	   a	   Dde	   (1-­‐(4,4-­‐dimethyl-­‐2,6-­‐
dioxocyclohexylidene)ethyl)-­‐protected	   2-­‐aminohexadecanoic	   acid	   lipoamino	   acid.26	   6-­‐
Maleimidohexanoic	  acid	  was	  synthesized	  as	  previously	  described,14	  with	  modifications	  
(see	   supplemental	   information).	   The	   lipoamino	   acid	   and	   6-­‐maleimidohexanoic	   acid	  
were	   incorporated	  without	  microwave	   heating.	   Peptides	  were	   cleaved	   from	   the	   resin	  
using	   trifluoroacetic	   acid	   (TFA),	   and	   purified	   to	   homogeneity	   by	   RP-­‐HPLC	   on	   a	   C4	  




Bioconjugation	   reactions	   (Figure	   1,	   A)	   were	   performed	   at	   37	   °C	   for	   30	   min	   in	   6	   M	  
guanidine-­‐HCl,	   50	   mM	   sodium	   phosphate	   pH	   7.3,	   20	   %	   acetonitrile,	   5	   mM	  
ethylenediaminetetraacetic	  acid	  (EDTA)	  containing	  ~	  2	  mg/mL	  of	  1	  and	  4-­‐5	  eq	  of	  2	  or	  
3.	   Adjuvants	   (2,	   3)	   were	   dissolved	   in	   dimethyl	   sulfoxide	   (DMSO;	   to	   4	   %	   (v/v)	   final	  
concentration)	  before	  their	  addition.	  Lipoprotein	  products	  (4,	  5)	  were	  purified	  by	  RP-­‐





Lipoproteins	   (4,	   5)	   were	   dissolved	   to	   1	   mg/mL	   in	   phosphate	   buffered	   saline	   (PBS).	  
Thrombin	   from	   human	   plasma	   (6	   U/mg	   of	   4	   or	   5)	   was	   added,	   and	   the	   mixture	  
incubated	  at	  37	  °C	  for	  3	  h.	  Lipoprotein	  products	  (6,	  7)	  were	  purified	  by	  RP-­‐HPLC	  on	  a	  
C4	  stationary	  phase.	  
	  
Characterization	  of	  lipoprotein	  vaccines	  
	  
Lipoprotein	   vaccines	   were	   characterized	   according	   to	   the	   following	   parameters:	   A.	  
molecular	   weight	   (electrospray	   ionization	   mass	   spectrometry	   (ESI-­‐MS),	   and	   sodium	  
dodecyl	   sulfate	   polyacrylamide	   gel	   electrophoresis	   (SDS-­‐PAGE);	   Figure	   1,	   C	   and	   D;	  
Figure	  S3;	  Figure	  S4),	  B.	  purity	  (RP-­‐HPLC,	  SDS-­‐PAGE,	  ESI-­‐MS;	  Figure	  1,	  C	  and	  D;	  Figure	  
S3,	   Figure	   S4),	   C.	   correct	   sequence	   (Sanger	   sequencing,	   ESI-­‐MS,	   peptide	   mass	  
fingerprinting	  (PMF)	  after	  Asp-­‐N	  digestion	  of	  4;	  Figure	  1,	  C	  and	  D;	  Figure	  S5,	  C),	  D.	  site-­‐
specific	   conjugation	   (PMF;	  Figure	  S5),	  E.	  particle	   size	   (dynamic	   light	   scattering	   (DLS),	  
transmission	   electron	   microscopy	   (TEM);	   Figure	   3,	   A	   and	   B),	   F.	   endotoxin	  
contamination	  (calorimetric	  Limulus	  amebocyte	  lysate	  (LAL)	  assay),	  G.	  oligonucleotide	  




Immunization was performed under protocols approved by the Griffith University 
(BDD/06/10/AEC) and University of Queensland 
(SCMB/GRIFITH/005/12/MERCK/NIH/NHF/NHMRC) animal ethics committees.	   The	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immunization	  schedule	  was	  based	  on	  kinetic	  data	  for	  antibody	  induction	  obtained	  from	  
mice	   immunized	   with	   a	   synthetic	   LCP	   system	   (incorporating	   three	   GAS	   M	   protein	  
antigens).27	   Each	   immunogen	   (1,	   6,	   and	   7;	   30	   μg/injection	   in	   50	   μL;	   A280	  quantified	  
stock	  solutions)	  was	  administered	  subcutaneously	  at	   the	   tail	  base	   in	  C57BL/6J	   (H-­‐2b)	  
mice	  (5/group).	  PBS	  sham	  immunization	  was	  used	  as	  a	  negative	  control.	  Mice	  receiving	  
1	   were	   primed	   with	   a	   1:1	   emulsion	   of	   PBS	   (containing	   1)	   and	   complete	   Freund’s	  
adjuvant	   (CFA).	   Administration	   of	   lipoproteins	   (6,	   7),	   and	   boosting	   with	   1,	   was	  
performed	  with	  PBS	  solubilized	  immunogens.	  Mice	  were	  boosted	  21	  days	  after	  priming,	  
and	  received	  a	  further	  2	  boosts	  at	  7-­‐day	  intervals.	  Final	  bleeds	  were	  collected	  from	  the	  
tail	  artery	  one	  week	  after	  the	  final	  boost.	  
	  
Enzyme-­‐linked	  immunosorbent	  assay	  (ELISA)	  
	  
An	  ELISA	  was	  performed	  to	  measure	  antigen-­‐specific	  serum	  IgG	  antibody	  titers	  against	  
the	   eight	   M	   protein	   antigens,	   for	   each	   individual	   mouse,	   essentially	   as	   described.17	  
Antibody	   titers	  were	   defined	   as	   the	   lowest	   dilution	  with	   an	  OD450	   value	   greater	   than	  
three	  standard	  deviations	  above	  the	  mean	  absorbance	  of	  control	  wells	  (sera	  from	  PBS	  
immunized	   mice).	   ELISA	   data	   (Figure	   4)	   is	   expressed	   as	   mean	   antigen-­‐specific	   IgG	  
antibody	   titer.	  Error	  bars	   indicate	   the	   standard	  error	  of	   the	  mean	   (SEM).	  Raw	  data	   is	  




Confocal	   immunofluorescence	  microscopy	   was	   used	   to	   qualitatively	   demonstrate	   the	  
binding	   of	   pooled	   antibodies	   elicited	   in	   response	   to	   vaccination	  with	  1	   (primed	  with	  
10	  
CFA),	   or	  6	   to	   the	   surface	   of	   GAS	   strains	   represented	   in	   our	   vaccine	   (Figure	   5,	  B),	   as	  
described.28	   The	   following	   strains	   were	   used:	   88/30 (emm97), PL1 (emm54), NS1 
(emm100), Y504S (emm11), BSA10 (emm2.3), NS27 (emm91), NS5 (emm101), and pM1 
(emm1; for J14).	  The confocal microscope was calibrated for positive and negative samples 
using pM1 GAS and murine antisera against recombinant M1 M protein or arginine 
deiminase (ADI)19 as positive controls, or antisera from sham (PBS) immunized mice as a 




Production	  of	  semisynthetic	  lipoprotein	  vaccine	  building	  blocks	  
	  
Recombinant	   protein	   1	   expressed	   as	   insoluble	   inclusion	   bodies	   and	   in	   the	   soluble	  
cytoplasmic	  fraction	  (Figure	  2,	  B).	  Purification	  yielded	  at	   least	  20	  mg	  of	  homogeneous	  
protein	  (per	   liter	  culture),	   suitable	   for	  conjugation	   to	   lipid	  adjuvants	  2	  or	  3.	  The	   lipid	  
adjuvants	  were	  readily	  synthesized	  by	  Fmoc-­‐SPPS	  and	  purified	  to	  homogeneity	  (Figure	  
S1,	  B	  and	  C)	  with	  a	  moderate	  overall	  yield	  (2:	  43	  %;	  3:	  38	  %).	  Attempts	  to	  simplify	  the	  
lipid	   adjuvant	   peptides,	   through	   deletion	   of	   the	   peptide	   (DCpep	   or	   CONTROLpep)	  
sequences,	  yielded	  hydrophobic	  molecules	  that	  were	  challenging	  to	  purify	  or	  use	  for	  the	  
bioconjugation	  reactions.	  
	  
Maleimide	  conjugation	  reaction	  
	  
The	  conditions	  used	  for	  bioconjugation	  of	  recombinant	  protein	  1	  to	  the	  lipid	  adjuvants	  
(2,	  3;	  Figure	  1,	  A)	  were	  optimized.	  High	  yielding	  (4:	  71	  %;	  5:	  89	  %),	  rapid	  (<	  15	  min),	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and	   complete	   reactions	   were	   achieved	   at	   37	   °C	   under	   denaturing	   conditions	   (6	   M	  
guanidine),	  with	  20	  %	  (v/v)	  acetonitrile	  as	  a	  cosolvent.	  Lipid	  adjuvants	  (2	  or	  3;	  4-­‐5-­‐fold	  
excess	  over	  1)	  were	  added	  to	  the	  reaction	  after	  dissolving	  in	  DMSO.	  The	  direct	  addition	  
of	   2	   or	   3,	   or	   use	   of	   N,N-­‐dimethylformamide	   (DMF)	   for	   their	   dissolution	   resulted	   in	  
lower	  product	  yields	  (e.g.	  26	  %	  yield	  for	  5	  when	  3	  was	  dissolved	  in	  DMF).	  Further,	  the	  
addition	   of	   tris(2-­‐carboxyethyl)phosphine	   (TCEP)	   to	   maintain	   a	   reduced	   	   cysteine,	  
generated	   an	   addition	   product	   with	   2	   or	   3,	   that	   was	   unable	   to	   participate	   in	   the	  
bioconjugation	   reaction.	   Lipid	   adjuvant	   attachment	  was	   also	   found	   to	   progress	   under	  
native	  conditions	  (e.g.	  in	  PBS),	  with	  slower	  reaction	  kinetics,	  some	  precipitation	  of	  2	  or	  
3,	  and	  reduced	  reaction	  progress.	  Lipoprotein	  products	  (4,	  5;	  Figure	  1,	  A)	  were	  easily	  
removed	   from	   other	   reaction	   components	   by	   RP-­‐HPLC	   (Figure	   1,	   B),	   enabling	   their	  
simple	  purification.	  The	  His-­‐tags	  were	  subsequently	  removed	  using	  thrombin	  (Figure	  1,	  
A),	  in	  a	  high	  yielding	  (6:	  89	  %;	  7:	  75	  %)	  and	  clean	  reaction	  (Figure	  1,	  C	  and	  D).	  
	  
Characterization	  of	  lipoprotein	  vaccines	  
	  
The	   molecular	   weights	   of	   lipoprotein	   products	   6	   and	   7	   were	   confirmed	   by	   ESI-­‐MS	  
(Figure	   1,	   C	   and	   D),	   with	   each	   product	   obtained	   at	   greater	   than	   99	   %	   purity	   (by	  
analytical	   RP-­‐HPLC	   area	   under	   the	   curve	   analysis).	   Evidence	   for	   site-­‐specific	   lipid	  
adjuvant	  conjugation	  was	  obtained	  via	  Asp-­‐N	  digestion	  of	  4,	  followed	  by	  PMF	  using	  RP-­‐
HPLC	   and	   ESI-­‐MS.	   This	   experiment	   generated	   a	   single	   hydrophobic	   peptide,	  
corresponding	  with	  the	  C-­‐terminus	  (25	  amino	  acids)	  of	  1	  conjugated	  to	  2	  (Figure	  S5,	  B),	  
with	   the	   other	   proteolytic	   peptides	   providing	   79.8	   %	   coverage	   of	   the	   lipoprotein	   4	  
sequence	  (Figure	  S5,	  C).	  The	  particle	  size	  of	  the	  purified	  vaccines	  (in	  PBS)	  was	  analyzed	  
by	  TEM	  (Figure	  3,	  A)	  and	  DLS	  (Figure	  3,	  B),	  revealing	  single	  mono-­‐	  (6	  polydispersity:	  15	  
12	  
%)	  or	  medium-­‐disperse	   (7	   polydispersity:	   24	  %)	  nanoparticle	   populations,	  with	   a	   40	  
nm	  average	  particle	  size	  (6:	  39	  nm;	  7:	  43	  nm).	  The	  vaccines	  were	  further	  analyzed	  for	  
the	   presence	   of	   immunostimulatory	   contaminants	   using	   an	   LAL	   endotoxin	   assay,	   and	  
agarose	  gel	  electrophoresis.	  Endotoxin	  levels	  were	  below	  the	  standard	  curve	  lower	  limit	  
(<	   0.1	   EU/mL),	   indicating	   that	   endotoxin	   contamination	   was	   significantly	   below	  
pharmacopoeial	   limits	   (USP/BP),	   and	   no	   oligonucleotide	   contamination	  was	   detected	  
(data	  not	  shown).	  
	  
Assessment	  of	  the	  immune	  response	  to	  lipoproteins	  
	  
Systemic	  antigen-­‐specific	  IgG	  antibody	  titers	  were	  quantified	  by	  ELISA	  at	  the	  final	  bleed	  
(day	  42)	   (Figure	  4;	  Figure	  S6).	  Antibodies	   targeting	  all	   eight	  M	  protein	  antigens	  were	  
detected	  in	  mice	  immunized	  with	  lipoproteins	  6	  or	  7,	  in	  addition	  to	  the	  positive	  control	  
group	  (mice	  primed	  with	  1	  in	  CFA)	  (Figure	  4;	  Figure	  S6),	  verifying	  that	  the	  lipoprotein	  
vaccines	  possess	  inbuilt	  adjuvant	  activity.	  A	  comparison	  of	  the	  antigen-­‐specific	  antibody	  
levels	   in	  mice	  administered	  6	  or	  7	   revealed	  a	   trend	  towards	  higher	  antibody	   levels	   in	  
mice	   immunized	  with	  6	   (Figure	   4;	   Figure	   S6),	  which	   contains	   a	  DC	   targeting	   peptide	  
(DCpep).	   This	   relationship	   was	   statistically	   significant	   for	   the	   BSA10	   (P	   ≤	   0.01)	   and	  
NS27	  (P	  ≤	  0.05)	  antigens.	  	  
	  
The	   level	  of	  anti-­‐Y504S	  antibodies	  was	  observed	  to	  be	  1-­‐5	  orders	  of	  magnitude	   lower	  
than	  observed	  for	  other	  antigens	  (Figure	  4;	  Figure	  S6).	  This	  effect	  was	  apparent	  for	  both	  
the	   lipoprotein	   (6,	   7)	   and	   positive	   control	   (1	   with	   CFA	   priming)	   groups.	   Anti-­‐J14	  
antibodies	  were	  also	  considerably	  lower	  (~	  1400-­‐fold)	  in	  the	  lipoprotein	  groups	  (4.6	  ×	  
102	  mean	  titer	  for	  6)	  compared	  with	  the	  positive	  control	  group	  (6.3	  ×	  105	  mean	  titer;	  P	  
13	  
≤	  0.05)	  (Figure	  4;	  Figure	  S6).	  The	  level	  of	  these	  antibodies	  in	  the	  positive	  control	  group	  
was	   similar	   to	   the	   levels	   observed	   for	   antigens	   other	   than	   Y504S,	  with	   high	   levels	   of	  
anti-­‐p145	  antibodies	  (2.9	  ×	  105	  mean	  titer),	  which	  measure	  anti-­‐J14	  antibody	  binding	  to	  
the	  correctly	  folded	  J14i	  antigen,17	  also	  detected.	  	  
	  
Confocal	  immunofluorescence	  microscopy	  was	  used	  to	  qualitatively	  assess	  the	  binding	  
of	  antibodies	  to	  a	  panel	  of	  GAS	  strains	  representing	  the	  eight	  vaccine	  M	  protein	  antigens	  
(Figure	   5,	   B).	   Similar	   to	   the	   ELISA	   data,	   strong	   binding	   was	   observed	   in	   all	   strains,	  
where	  antisera	  from	  the	  positive	  control	  group	  were	  used,	  with	  the	  exception	  of	  Y504S.	  
Similar,	   but	   visually	   weaker	   binding	   was	   observed	   where	   sera	   from	   lipoprotein	   6	  
immunized	  mice	  were	  assessed,	  with	  reduced	  binding	  to	  pM1	  GAS	  (which	  only	  includes	  
the	  J14i	  antigen	  in	  its	  M	  protein)	  in	  addition	  to	  the	  Y504S	  strain.	  
	  
Discussion	  
The	   technology	   established	  herein	   allows	   for	   simple	   and	   efficient	   generation	   of	   lipid-­‐
adjuvanted	   protein	   vaccines.	   It	   is	   ideal	   for	   vaccines	   incorporating	   denatured	   protein	  
antigens,	   for	   which	   fast	   and	   complete	   bioconjugation	   reactions	   were	   observed.	   This	  
favors	  the	  polytope	  approach,	  since	  the	  majority	  of	  epitopes	  used	  (N-­‐terminal	  M	  protein	  
antigens	  and	  PADRE1024.03)	  do	  not	  require	  a	  specific	  fold,29	  and	  J14	  readily	  refolds	  on	  
its	   own.17,	   30	   In	   addition	   to	   this	   advantage,	   polytopes	   enable	   the	   incorporation	   of	  
multiple	  defined	  epitopes	  within	  a	  single	  immunogen,	  greatly	  enhancing	  the	  capacity	  to	  
elicit	   broad	   protective	   immunity	   compared	   with	   single	   epitope	   approaches,31	   and	  
permit	  the	  incorporation	  of	  large	  antigens	  that	  are	  beyond	  the	  size	  accessible	  to	  peptide	  
synthesis.11,	  31	  The	  technology	  may	  also	  be	  used	  with	  full-­‐length	  natural	  proteins,	  their	  
mutants,	   or	   immunogenic	   fragments.	   This	   requires	   the	   addition	   of	   a	   C-­‐terminal	   or	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internal	   cysteine	   residue	   to	   enable	   maleimide	   conjugation,	   with	   N-­‐terminal	   fusions	  
discouraged	   due	   to	   their	   reactivity	   with	   aldehyde/ketone	   metabolites	   during	  
expression.32	   Proteins	   that	   contain	   cysteine	   may	   also	   be	   incorporated	   where	  
conservative	  cysteine	  mutations	  (e.g.	  to	  serine	  or	  alanine)	  maintain	  the	  capacity	  to	  elicit	  
protective	   immunity.	  Alternatively,	  where	  cysteine	  residues	  are	  buried,	  or	   involved	   in	  
disulfide	  bonds,	  this	  approach	  may	  prove	  successful	  if	  native,	  non-­‐reducing	  conjugation	  
conditions	  are	  used.	  
	  
Synthesis	  of	  polytope	  genes	   is	   efficient,	   relatively	   inexpensive,	   and	  provides	  access	   to	  
improved	  expression	  yields	  through	  codon	  optimization	  for	  industrial	  scale	  expression	  
hosts.33	  The	  gene	  used	  herein	  could	  be	  readily	  assembled	  by	  gene	  synthesis	  PCR25	  (or	  
alternatively	   outsourced	   e.g.	   to	   DNA2.0),	   and	   inserted	   into	   expression	   vectors	   using	  
restriction-­‐free	  cloning.34	  The	  gene	  product	  could	  then	  be	  overexpressed	  in	  E.	  coli,	  and	  
purified	   under	   denaturing-­‐reducing	   conditions	   to	   solubilize	   inclusion	   bodies	   and	  
maintain	   cysteine	   residues	   in	   a	   reduced	   state.	   In	   addition	   to	   the	   aforementioned	  
advantages,	   the	   purification	   of	   polytope	   antigens	   under	   denaturing	   conditions	   is	   of	  
significant	  advantage	  where	  protein	  is	  predominantly	  expressed	  in	  inclusion	  bodies,	  as	  
protein	  enrichment	  can	  be	  achieved	  through	  simple	  lysis,	  centrifugation,	  and	  detergent	  
washes,	  and	  purification	  achieved	  without	  the	  need	  for	  costly	  affinity	  purification	  steps	  
(e.g.	  by	  size	  exclusion,	  or	  ammonium	  sulfate	  cuts).35	  
	  
Several	   approaches	   were	   taken	   to	   optimize	   the	   bioconjugation	   reaction	   conditions.	  
These	   included:	   avoiding	   thiol	   (e.g.	   2-­‐ME)	   or	   phosphine	   (e.g.	   TCEP)	   reducing	   agents,	  
which	  were	   detrimental	   to	   the	   conjugation	   reaction;	   the	   addition	  of	   EDTA	   to	  prevent	  
metal	   catalyzed	   cysteine	   oxidation;15	   maintaining	   near	   neutral	   pH	   to	   reduce	   the	  
15	  
oxidation	   rate;	   and	   the	   addition	   of	   lipid	   adjuvants	   in	   excess,	   to	   drive	   reactions	   to	  
completion.	  The	  hydrophobic	  nature	  of	  the	  lipid	  adjuvants	  necessitated	  solubilization	  in	  
an	  organic	  solvent	  prior	  to	  use,	  with	  DMSO	  proving	  ideal	  (fast	  reaction	  rates	  (<15	  min)	  
and	   high	   yields	   (>	   71	   %)),	   despite	   concerns	   about	   its	   capacity	   to	   promote	   cysteine	  
oxidation.36	  
	  
Prior	  to	  assessing	  lipoprotein	  vaccines	  in	  mice,	  the	  His-­‐tags	  were	  removed	  (Figure	  1,	  A)	  
in	  order	  to	  minimize	  effects	  on	  J14	  folding,	  or	  reduction	  in	  vaccine	  efficacy	  due	  to	  tag-­‐
directed	  immunity.37	  Quantified	  vaccine	  stock	  solutions	  were	  then	  produced	  to	  ensure	  
administration	   of	   equivalent	   vaccine	   doses,	   and	   further	   characterized	   to	   verify	   their	  
freedom	   from	   endotoxin	   contamination.	   This	   step	   is	   important	   for	   immunogens	  
expressed	   in	   E.	   coli,	   which	   produces	   endotoxins	   that	   could	   contaminate	   the	   final	  
product.38	   Such	   contamination	   could	   contribute	   to	   adjuvant	   activity,	   complicating	   the	  
assessment	  of	  lipoprotein	  vaccine	  associated	  immunostimulation.	  
	  
The	  site-­‐specific	  nature	  of	  the	  bioconjugation	  reaction	  is	  also	  important	  for	  the	  success	  
of	  this	  platform	  because	  it	  ensures	  that	  a	  single	  vaccine	  product	  is	  produced,	  which	  can	  
be	  characterized	  at	  the	  molecular	  level.	  Since	  the	  maleimide-­‐species	  was	  used	  in	  excess,	  
we	   sought	   evidence	   that	   adjuvant	   conjugation	   occurred	   exclusively	   through	   the	  
cysteine.	  This	  was	  important,	  as	  maleimides	  may	  also	  react	  with	  amines,	  although	  at	  a	  
slower	  rate	  under	  the	  pH	  conditions	  used.15	  A	  PMF	  approach	  provided	  an	  ideal	  means	  
to	   assess	   the	   site-­‐specificity	   of	   the	   conjugation	   reaction.	   By	   selecting	   a	   protease	   that	  
does	  not	  cut	  within	  the	   lipid	  adjuvant,	  proteolytic	  peptides	   fused	  to	  the	   lipid	  adjuvant	  
are	   specifically	   generated	   at	   sites	   where	   conjugation	   occurred.	   The	   extreme	  
hydrophobicity	  of	  these	  peptides	  enables	  their	  sorting	  from	  other	  proteolytic	  species	  by	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RP-­‐HPLC	   for	  subsequent	  characterization	  by	  ESI-­‐MS.	   In	   this	  case	  Asp-­‐N	  digestion	  of	  4	  
generated	  a	  single	  hydrophobic	  peptide,	  corresponding	  with	  conjugation	  through	  the	  C-­‐
terminus	  of	  1	   (Figure	  S5,	  A	  and	  B).	  This	  data	  strongly	  supported	  that	  conjugation	  was	  
site-­‐specific	  and	  occurred	  through	  the	  C-­‐terminal	  cysteine.	  
	  
The	   lipoprotein	   vaccines	   were	   further	   characterized	   by	   TEM	   and	   DLS	   to	   investigate	  
their	  capacity	  to	  form	  particles	  following	  addition	  to	  aqueous	  buffers.	  Both	  techniques	  
revealed	   that	   lipoproteins	  6	   and	  7	   form	  ~	  40	  nm	  diameter	  nanoparticles	   (Figure	  3,	  A	  
and	   B).	   This	   information	   was	   important	   because	   particle	   size	   is	   known	   to	   have	   a	  
significant	  effect	  on	  antigen	  transport	  to	  secondary	  lymphoid	  organs,	  uptake	  by	  antigen	  
presenting	  cells,	  cross-­‐presentation,	  and	  potency	  of	  the	  immune	  response.39	  Particles	  in	  
the	   10-­‐200	   nm	   range	   (with	   ~	   40	   nm	   particles	   considered	   optimal)39	   enter	   lymph	  
vessels	   through	   gaps	   between	   endothelial	   cells.	   Following	   parenteral	   administration,	  
these	   particles	   reach	   the	   lymph	   node	  within	   hours,	   and	   can	   access	   both	   B	   and	  T	   cell	  
regions.	   In	   comparison,	   particles	   that	   are	   larger	   than	   200-­‐500	   nm	   require	   cellular	  
transport	  (e.g.	  by	  DCs)	  to	  reach	  the	  lymphatic	  system.39	  This	  takes	  upwards	  of	  24	  hours,	  
reducing	  the	  amount	  of	  native	  antigen	  presented	  to	  B	  cells,	  and	  restricting	  access	  to	  T	  
cell	  regions	  in	  the	  lymph	  nodes.	  Based	  on	  this	  knowledge,	  our	  nanoparticles	  appear	  to	  
fall	   within	   the	   optimum	   size	   range	   for	   eliciting	   potent	   antibody-­‐mediated	   immunity,	  
which	  is	  desirable	  for	  this	  application.	  
	  
Lipoprotein	   vaccines	   (6,	   7)	   were	   administered	   subcutaneously	   to	   C57BL/6J	   mice	   to	  
assess	   their	   ability	   to	   stimulate	   protective	   antibody-­‐mediated	   immunity,	   without	   the	  
need	   for	   coadministration	   with	   an	   adjuvant.	   Polytope	   1,	   with	   CFA	   priming,	   was	  
administered	  as	  a	  positive	   control.	  This	   combination	   is	  not	   suitable	   for	  human	  use	  as	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CFA	   is	   associated	  with	   significant	   toxicity.40	   Both	   polytope	   (1	   primed	  with	   CFA)	   and	  
lipoprotein	   (6,	   7)	   vaccines	   raised	   systemic	   IgG	   antibodies	   against	   all	   eight	   polytope	  
antigens	  (Figure	  4;	  Figure	  S6).	  This	  validated	  that	  the	  polytope	  approach	  was	  suitable	  
for	   the	   selected	   antigens,	   and	   verified	   the	   immunostimulatory	   activity	   of	   the	   lipid	  
adjuvants,	  respectively.	  A	  trend	  towards	  higher	  systemic	  antigen-­‐specific	  IgG	  antibody	  
titers	  was	  also	  observed	  in	  mice	  immunized	  with	  6	  compared	  with	  7	  (Figure	  4;	  Figure	  
S6).	   This	   is	   likely	   because	   lipoprotein	   6	   incorporates	   DCpep,	   which	   has	   been	  
demonstrated	   to	  specifically	  bind	   to	   the	  surface	  of	  DCs	   from	  various	  animal	  species.24	  
Antigen	  fusions	  with	  DCpep	  provide	  a	  means	  to	  target	  DCs,	  and	  have	  been	  observed	  to	  
increase	  antigen	  uptake,	  processing	  and	  presentation,	   leading	  to	  more	  potent	  antigen-­‐
specific	  immunity.24,	  41,	  42	  Although	  antigen-­‐specific	  IgG	  antibodies	  were	  elicited	  against	  
each	   polytope	   antigen,	   Y504S1-­‐20	   was	   weakly	   immunogenic	   in	   the	   context	   of	   the	  
polytope	   (Figure	   4;	   Figure	   S6).	   Similar	   observations	   were	   made	   for	   J14	   in	   the	  
lipoprotein	  groups,	  while	  high	  levels	  of	  anti-­‐J14	  and	  p145	  antibodies	  were	  observed	  for	  
CFA	  primed	  mice	  (Figure	  4;	  Figure	  S6).	  
	  
To	   further	   characterize	   the	   functional	   significance	   of	   antibodies	   raised	   against	   our	  
lipoprotein	   vaccines,	   we	   turned	   to	   a	   confocal	   immunofluorescence	   microscopy	  
approach.	   Antibodies	   targeting	   N-­‐terminal	   M	   protein	   antigens18	   and	   J1443	   have	   been	  
demonstrated	  to	  elicit	  protective	  (i.e.	  opsonic)	  antibody	  responses.	  By	  investigating	  the	  
binding	  of	  antibodies	  elicited	  against	  our	  lipoproteins	  to	  the	  eight	  vaccine	  represented	  
GAS	  strains,	   the	  protective	  potential	  offered	  by	  these	  antibodies	  can	  be	  assessed.	  This	  
assay	  also	  evaluates	  binding	   in	  the	  context	  of	   the	  native	  bacterium,	  ensuring	  native	  M	  
protein	   folding,	   and	  maintains	   factors	   that	  may	   reduce	   the	   antibody	   binding	   capacity	  
(e.g.	  the	  hyaluronic	  acid	  capsule).28	  The	  results	  of	  this	  assay	  (Figure	  5,	  B)	  demonstrated	  
18	  
that	  antibodies	  raised	  against	  lipoprotein	  6	  bound	  all	  eight	  GAS	  strains	  represented	  in	  
the	   vaccine,	   although	   fluorescence	   associated	   with	   pM1	   (which	   expresses	   the	   J14i	  
epitope)	  or	  Y504S	  (emm11)	  binding	  was	  lower	  than	  for	  the	  other	  antigens.	  
	  
Overall,	   this	   research	   has	   provided	   a	   method	   to	   enable	   the	   simple,	   high	   yielding	  
conjugation	  of	  recombinant	  protein	  antigens	  to	  LCP-­‐based	  lipid	  adjuvants.	  The	  capacity	  
to	  combine	  recombinant	  and	  synthetic	  approaches	  enables	   the	  production	  of	  vaccines	  
of	   a	   size	   greater	   than	   would	   be	   accessible	   by	   synthetic	   means	   alone,	   with	   the	   site-­‐
specific	   bioconjugation	   chemistry	   generating	   a	   chemically	   defined	   product.	   The	  
polytope	  approach	  offers	   further	  advantages	  by	  permitting	   the	   incorporation	  of	  many	  
defined	  peptide	  epitopes,	  producing	  a	  more	  focused	  immune	  response	  compared	  with	  
the	   use	   of	   whole	   proteins,	   and	   enables	   the	   incorporation	   of	   epitopes	   from	   multiple	  
sources.	  As	  a	  model	  for	  developing	  this	  platform,	  the	  lipid	  adjuvant	  was	  conjugated	  to	  a	  
polytope	   incorporating	   eight	   GAS	   M	   protein	   antigens.	   This	   construct	   displayed	   self-­‐
adjuvanting	   activity,	   formed	   particles	   of	   an	   optimal	   size	   for	   generating	   antibody-­‐
mediated	   immunity,	   and	  elicited	   antibodies	   against	   each	  polytope	   antigen	   that	  bound	  
their	  respective	  GAS	  strain.	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Figure	   1.	  Maleimide	   conjugation	   reaction.	   (A)	   The	   conjugation	   between	   recombinant	  
antigen	   1	   and	   lipid	   adjuvant	   peptides	   2	   or	   3	   and	   subsequent	   His-­‐tag	   cleavage	   is	  
depicted,	   along	   with	   the	   structure	   of	   the	   lipid	   adjuvant	   peptides.	   (B)	   HPLC	  
chromatogram	   for	   the	   conjugation	  of	  1	   and	  2,	   demonstrating	   the	   separation	  between	  
starting	  material	  (1,	  2)	  and	  product	  (4).	  (C)	  and	  (D)	  HPLC,	  reconstructed	  mass	  spectra,	  
and	  SDS-­‐PAGE	  data	  for	  purified	  lipoproteins	  6	  and	  7,	  respectively.	  
	  
Figure	   2.	   Synthesis,	   cloning	   and	   expression	   of	   recombinant	   polytope	   antigen	   1.	   (A)	  
Scheme	   depicting	   the	   production	   of	   recombinant	   polytope	   1,	   with	   the	   antigen	  
arrangement	  and	  protein	  sequence	  shown.	  (B)	  Analysis	  of	  protein	  1	  expression	  by	  SDS-­‐
PAGE.	   Lanes	   show	   uninduced	   (UN)	   and	   induced	   (IN)	   whole	   cell	   fractions,	   as	   well	   as	  
inclusion	  body	  (IB)	  and	  soluble	  cytoplasmic	  fractions	  following	  lysis.	  (C)	  Reconstructed	  
mass	  spectra,	  (D)	  HPLC,	  and	  (E)	  SDS-­‐PAGE	  data	  for	  purified	  antigen	  1.	  
	  
Figure	   3.	   Lipoproteins	   6	   and	   7	   form	   nanoparticles	   in	   aqueous	   buffers.	   (A)	   TEM	  
demonstrates	   the	   formation	  of	   lipoprotein	  nanoparticles.	  (B)	  Dynamic	   light	  scattering	  
(6	  replicates)	  shows	  that	  these	  particles	  have	  an	  average	  diameter	  of	  ~	  40	  nm.	  
	  
Figure	   4.	   Assessment	   of	   antigen-­‐mediated	   immunity	   elicited	   in	   response	   to	  
subcutaneous	   immunization	   with	   recombinant	   antigen	   1	   (primed	   with	   CFA),	  
lipoprotein	  6	   (includes	  DCpep)	   or	  7	   (includes	   CONTROLpep),	   or	   PBS	   sham	   (negative	  
control).	  An	  ELISA	  was	  used	  to	  measure	  the	  antigen-­‐specific	  serum	  IgG	  antibody	  titers	  
(log10),	   against	   the	   eight	   polytope	   antigens,	   from	   individual	   sera	   collected	   one-­‐week	  
25	  
after	   the	   final	  boost.	  Plates	  were	  coated	  with	  synthetic	  peptide	  antigens.	  The	  capacity	  
for	   antibodies	   against	   J14	   to	   bind	   the	   folded	   J14i	   conformational	   epitope	   was	  
demonstrated	  using	  p145.	  Data	  is	  expressed	  as	  mean	  antigen-­‐specific	  IgG	  antibody	  titer.	  
Error	  bars	  represent	  the	  standard	  error	  of	  the	  mean	  (SEM).	  
	  
Figure	  5.	  Confocal	  immunofluorescence	  (right	  panels)	  and	  DIC	  (left	  panels)	  microscopy	  
of	  GAS	  strains	  represented	  within	  the	  polytope	  sequence	  (pM1	  M	  protein	  incorporates	  
J14i).	  (A)	  Positive	  and	  negative	  controls.	  Antisera	  from	  mice	  immunized	  with	  M1	  or	  ADI	  
(with	  CFA	  priming)	  were	  used	  as	  positive	  controls,	  with	  pooled	  antisera	  from	  PBS	  sham	  
immunized	  mice	  used	  as	  a	  negative	  control	  for	  binding	  pM1	  GAS.	  (B)	  Stationary	  phase	  
bacteria	   were	   incubated	   with	   pooled	   antisera	   (1:200)	   from	   mice	   immunized	   with	   1	  
(primed	  with	   CFA),	   lipoprotein	  6,	   or	   PBS	   sham	   (negative	   control),	   labeled	   with	   goat	  
anti-­‐mouse	   IgG-­‐FITC,	  and	  viewed	  with	  a	  100×	  oil-­‐immersion	  objective.	  An	  asterisk	   (*;	  
upper	   right)	   indicates	   that	   a	   1:50	   dilution	   of	   primary	   antisera	   was	   used.	   Scale	   bars	  
(upper	  left)	  indicate	  2	  μm.	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Materials and Methods 
Materials. Fmoc (fluorenylmethoxycarbonyl)-L-amino acids, O-(7-Azabenzotriazol-
1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU), 2-(1H-
benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) were 
purchased from Mimotopes (Clayton, VIC, Australia). Rink amide MBHA resin (100-
200 mesh; 0.59 mmol/g), methylene chloride (DCM; ACS grade), methanol (HPLC 
grade), N,N-dimethylformamide (DMF; peptide synthesis grade), and trifluoroacetic 
acid (TFA) were purchased from Merck Millipore (Kilsynth, VIC, Australia). MeCN 
(HPLC grade), and maleic anhydride were from Scharlau (Barcelona, Spain). 
Deuterated NMR solvents were purchased from Cambridge	   Isotope	   Laboratories,	  
(Andover,	   MA,	   USA). Lysogeny Broth (LB; Miller’s formulation), and IPTG were 
from Amresco (Solon, OH, USA). Thrombin from human plasma (≥1000 NIH 
units/mg protein; 0.5 U/µL in PBS; T7009), endoproteinase Asp-N (from 
Pseudomonas fragi mutant strain; 40 µg/mL in 10 mM Tris-Cl pH 8; P3303), and 
complete Freund’s adjuvant were from Sigma-Aldrich. The pTXB1 vector was from 
New England Biolabs (NEB; Ipswich, MA, USA). Phusion high-fidelity DNA 
polymerase, HisPur Nickel-nitriloacetic acid (Ni-NTA) resin, and dNTPs were from 
Thermo Scientific (Scoresby, VIC, Australia). The QuikChange XL II site-directed 
mutagenesis kit and BL21-codonplus (DE3)-RIL were from Agilent (La Jolla, CA, 
USA). Goat α-mouse IgG (H+L)-HRP conjugate was from Bio-Rad Laboratories 
(Gladesville, NSW, Australia). KOD DNA polymerase, and human plasma IgG 
(Calbiochem) was from Merck Millipore (Kilsyth, VIC, Australia). DNA purification 
kits (QIAprep spin minikit, QIAquick gel extraction kit, and QIAquick PCR 
purification kit) were from Qiagen (Chadstone, VIC, Australia). Oligonucleotides 
were purchased from Integrated DNA Technologies (IDT) (Coralville, IA, USA) with 
standard desalting. Peptide antigens for ELISA were synthesized on a Symphony 12-
channel multiplex peptide synthesizer (Protein Technologies, Tucson, AZ, USA) as 
C-terminal amides using standard instrument coupling protocols, or ordered from 
Mimotopes (Clayton, VIC, Australia). Titertek 96-well polyvinylchloride (PVC) 
microplates were from MP Biomedicals (Seven Hills, NSW, Australia). DPBS (1×) 
and goat anti-mouse IgG(H+L)-FITC conjugate (Zymed) were from Life 
Technologies (Mulgrave, VIC, Australia). Pyrochrome chromogenic reagent, 
Glucashield Buffer (β-glucan inhibiting buffer), Control standard endotoxin (CSE) 
Escherichia coli 0113:H10, and endotoxin free plasticware were from Associates of 
Cape Cod (East Falmouth, MA, USA). LAL reagent water, and pyrogen free test 
tubes were from Lonza (Mt Waverley, VIC, Australia). All other reagents were 
purchased from Sigma-Aldrich (Castle Hill, NSW, Australia) at the highest available 
purity. 
 
Equipment. Deionized double distilled H2O (ddH2O) was used throughout and was 
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prepared by a Millipore Simplicity UV ultrapure water system. Microwave-assisted 
manual peptide synthesis was performed on a CEM Discover SPS Microwave Peptide 
Synthesizer (CEM, Matthews, NC, USA). Cell lysis was performed using a Branson 
Sonifier 450A analog ultrasonic cell disruptor. Electrospray ionization-mass 
spectrometry (ESI-MS) was performed on a Perkin Elmer-Sciex API3000 triple 
quadrupole instrument using Analyst 1.4 software (Applied Biosystems-MDS Sciex, 
Framingham, MA, USA). Protein masses were reconstructed using BioAnalyst 1.5.1 
software (AB Sciex, Framingham, MA, USA). 1H and 13C-NMR spectra were 
recorded on a Bruker Avance 300 or 500 MHz spectrometers (Bruker Biospin, 
Germany) at 298 °K.	   Chemical	   shifts	   are	   reported	   in	   parts	   per	   million	   (ppm)	  
downfield	   from	   tetramethylsilane.	  NMR	   spectra	  were	  processed	  using	  Topspin	  
software	   (Bruker	   Biospin,	   Germany). UV-Vis spectroscopy was performed on a 
Cary 50 Bio Spectrophotometer with Cary WinUV Software (Varian	  Inc,	  Palo	  Alto,	  
CA,	  USA).	  Dynamic	  light	  scattering	  (DLS)	  particle	  size	  analysis	  was	  acquired	  on	  a	  
Zetasizer	   Nano	   ZS	   (Malvern	   Instruments,	   Worcestershire,	   UK)	   at	   25	   °C	   using	  
disposable	  cuvettes.	  Transmission	  electron	  microscopy	  (TEM)	  was	  performed	  on	  
a	  JEOL-­‐1010	  instrument	  (JEOL	  Ltd,	  Japan)	  operating	  at	  an	  accelerating	  voltage	  of	  
100	  kV.	  Samples	  were	  applied	  to	  glow	  discharged	  carbon	  coated	  200	  mesh	  grids	  
for	  3	  min,	  and	  then	  wicked	  off	  with	  filter	  paper.	  Microplate	  assays	  were	  read	  on	  a	  
SpectraMAX	   190	   plate	   reader	   with	   SoftMax	   Pro	   software	   (Molecular	   Devices,	  
Sunnyvale,	  CA,	  USA).	  DNA	  sequencing	  was	  performed	  by	  the	  Australian	  Genome	  
Research	   Facility	   (AGRF;	   Brisbane	   Node,	   the	   University	   of	   Queensland)	   on	   an	  
Applied	   Biosystems	   3730xl	   DNA	   analyzer	   using	   ABI	   Prism	   BigDye	   terminator	  
sequencing	   chemistry	   (version	   3.1).	   Confocal	   Microscopy	  was	   performed	   on	   a	  
Zeiss	   LSM	   510	   META	   confocal	   scan	   head	   mounted	   on	   an	   Axioplan	   2	   imaging	  
platform	   (Carl	   Zeiss,	   Jena,	   Germany).	   Data	   was	   acquired	   using	   AIM	   4.2	   LSM	  
software	  (Carl	  Zeiss).	   
 
Analytical reversed-phase high-performance liquid chromatography (RP-HPLC) was 
performed using a Shimadzu Prominence Analytical HPLC system (SIL-20AC HT 
autosampler, SPD-M10A Vp diode array detector, DGU-20A5 degasser, LC-20AB 
binary solvent delivery unit, CBM-20Alite card-type system controller, and 
Labsolutions 5.32 SP1 software). Preparative RP-HPLC was performed using a 
Shimadzu Preparative HPLC system (2 × LC-20AP large-scale preparative solvent 
delivery units, SPD-20A UV-Vis detector, FRC-10A fraction collector, CBM-20A 
system controller, 3725i-038 Rheodyne preparative scale manual sample injector, and 
Labsolutions 5.42 SP3 software). Separations were performed in gradient mode over 
30 min for analytical, and 60 min for preparative separations. Solvent A consisted of 
0.1 %(v/v) TFA in H2O. Solvent B consisted of 90 % (v/v) MeCN/0.1 %(v/v) TFA in 
H2O. Separation was achieved on C4 stationary phases, except for the GAS-Cys 
polytope, which was separated on a C18 stationary phase. The following columns 
(300 Å pore size) were used: 1) Vydac C4 analytical (214TP54; 250 × 4.6 mm; 5 
µm), 2) Vydac C18 analytical (218TP54; 250 × 4.6 mm; 5 µm), 3) Vydac C4 
preparative (214TP1022; 250 × 22 mm; 10 µm), and 4) Vydac C18 preparative 
(218TP1022; 250 × 22 mm; 10 µm). A flow-rate of 1 mL/min or 10 mL/min was used 
for analytical or preparative scale separations respectively, with detection at 214 nm 
for analytical and 230 nm for preparative runs. 
 
6-Maleimidohexanoic Acid Synthesis. The synthesis was performed as described by 
de Figueiredo, et al1 with modifications. Maleic anhydride (5 g; 51 mmol) and 
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aminohexanoic acid (6.7 g; 51 mmol) were refluxed (silicon oil bath, 170 °C) in dry 
glacial AcOH (40 mL) for 90 min. The reaction was cooled to RT, and the solvent 
removed by rotary evaporation. Residual AcOH was removed by coevaporation with 
toluene. The remaining residue was taken up in EtOAc (300 mL), washed with ddH2O 
(3 x 100 mL), then saturated aqueous NaCl (50 mL), dried (MgSO4), filtered, and 
concentrated. The mixture was purified on a 10 (h) × 10 (d) cm silica plug column, 
eluted with 1:4 hexane-EtOAc, concentrated, dissolved in boiling EtOAc, and 
recrystallized by dropwise addition of hexane to give 6-maleimidohexanoic acid (5.2 
g; 48 % yield) as a white powder. Characterization data matched that reported in the 
literature.1 
 
1H-NMR (300 MHz; CDCl3): δ 6.69 (2H, s), 3.52 (2H, t), 2.35 (2H, t), 1.56-1.70 (4H, 
m), 1.3-1.37 (2H, m). 
ESI-MS: [2M+H]+ m/z 423.5 (calcd. 423.4), [M+H]+ m/z 212.2 (calcd. 212.2). MW 
211.21 g/mol. 
TLC: Rf 0.55 (1:4 Hexane-EtOAc) 
 
2-Acetyldimedone (Dde-OH) Synthesis. DCC (33.9 g; 164 mmol), DMAP (20.0 g; 
164 mmol), and AcOH (9.9 g; 164 mmol) were added to a stirred suspension of 
dimedone (23 g; 164 mmol) in DCM (200 mL). The reaction was protected from 
light, and stirred for 16 h at RT. The reaction mixture was filtered, concentrated, 
taken up in EtOAc (200 mL), and washed with 5 % (v/v) HCl (3 x 100 mL), and 
saturated aqueous NaCl (50 mL). The organic phase was dried (MgSO4), filtered, and 
concentrated. The mixture was purified on a 10 (h) × 10 (d) cm silica plug column, 
eluting with hexane and concentrated to give Dde-OH (21.6 g; 73 % yield) as yellow 
crystals. Characterization data matched that reported in the literature.2  
 
1H-NMR (300 MHz; CDCl3): δ 2.59 (3H, s, CH3), 2.51 (2H, s, CH2), 2.36 (2H, s, 
CH2), 1.10 (6H, s, C(CH3)2). 
ESI-MS: [M+H]+ m/z 183.4 (calcd. 183.2). MW 182.22 g/mol. 
TLC: Rf 0.5 (2:3 EtOAc-Hexane) 
 
2-[[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl]amino]-hexadecanoic acid 
(Dde-C16-OH) Synthesis. To 2-Aminohexadecanoic acid hydrochloride (10 g; 32.5 
mmol) and Dde-OH (6.5 g; 35.7 mmol; 1.1 eq) in EtOH (200 mL) was added TEA 
(9.86 g; 97.4 mmol; 3 eq). The mixture was refluxed (silicon oil bath, 150 °C) for 2 
days, and subsequently cooled to RT. The reaction was filtered, concentrated (rotary 
evaporation), taken up in EtOAc (200 mL), and then washed with 5 % (v/v) HCl (3 x 
100 mL), and saturated aqueous NaCl (50 mL). The organic phase was dried 
(MgSO4), filtered, and concentrated (rotary evaporation) to give a yellow gum, which 
was purified on a 10 (h) × 10 (d) cm silica plug column. The product was eluted using 
a stepwise gradient (1:4 EtOAc-hexane to 100 % EtOAc) and concentrated to give 
Dde-C16-OH (10.5 g; 67 % yield) as a white powder. Characterization data matched 
that reported in the literature.2  
 
1H-NMR (400 MHz; CDCl3): δ 4.38 (1H, m, α-CH), 2.54 (3H, s, CH3CNH), 2.41 
(4H, s, 2 x CH2CO), 2.01-1.88 (2H, m, β-CH2), 1.45-1.20 (24H, m, 11 x CH2), 1.04 
(6H, s, C(CH3)2), 0.87 (3H, t, CH3). 
ESI-MS: [M+H]+ m/z 436.8 (calcd. 436.6). MW 435.64 g/mol. 
TLC: Rf 0.43 (90:8:2 CHCl3-MeOH-AcOH) 
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Peptide Synthesis. Peptides 2 and 3 were synthesized using a combination of manual 
solid-phase peptide synthesis (SPPS) and microwave assisted SPPS using HBTU (or 
HATU) for Dde-16-OH)/DIPEA in situ neutralization3 and Fmoc-chemistry on rink 
amide MBHA resin (0.59 mmol/g). Before commencing peptide synthesis, the resin 
was swollen in DMF (10 mL/g resin) for 2 h, with an Fmoc-deprotection step 
performed prior to coupling the first amino acid. Fmoc-deprotection was achieved by 
3 × 5 min treatments with 20 % (v/v) piperidine-DMF for manual synthesis steps, or 2 
× 5 min treatments at 60 °C for microwave assisted synthesis. Dde-deprotection was 
achieved by multiple 10 min treatments with 2 % (v/v) hydrazine hydrate in DMF. To 
ensure complete Dde-removal, UV monitoring at 300 nm was performed until no 
change in absorbance was observed. This typically required approximately 4 × 10 min 
treatments. After Fmoc and Dde deprotection steps, a 1 min DMF flow wash was 
performed, followed by 30-60 min couplings with 4 eq of preactivated amino acid for 
manual couplings. Microwave assisted couplings were assembled as per manual 
couplings, and performed for 5 min at 70 °C with dynamic heat control. Histidine and 
cysteine residues were coupled for 10 min at 50 °C to minimize racemization.4 
Acceleration of arginine γ-lactam formation occurs under microwave coupling 
conditions, reducing the concentration of activated arginine available to participate in 
peptide chain elongation. To minimize arginine deletion products a modified double 
coupling protocol from CEM was used (first coupling: 25 min at 25 °C, then 70 °C 
for 5 min; second coupling: 70 °C for 5 min).5 Amino acid activation was achieved by 
dissolving amino acids (4 eq) in 0.5 M HBTU or HATU-DMF solution (3.92 eq) to 
which DIPEA (5.68 eq) was added. Amino acids (except Fmoc-His(Trt)-OH) were 
preactivated for 1 min prior to their addition to the resin. Coupling yields were 
determined by the quantitative ninhydrin test6 for steps performed at RT. Where 
necessary, couplings were repeated to ensure coupling yields greater than 99.7 %. For 
microwave-assisted coupling steps amino acids were routinely double-coupled. Fmoc-
amino acids with the following side-chain protection were used: Arg(Pbf), Asn(Trt), 
Gln(Trt), Glu(tBu), His(Trt), Lys(Boc), Ser(tBu), Thr(tBu), Tyr(tBu). 
 
Peptides 2 and 3 were synthesized from a common resin-bound lipid adjuvant species. 
This compound was synthesized using manual SPPS (0.5 mmol scale). HATU was 
used for Dde-16-OH couplings, and HBTU for all other coupling steps. The lipid 
adjuvant sequence was assembled by coupling Fmoc-Gly-OH, followed by two copies 
of Dde-C16-OH, Fmoc-Gly-OH, and Dde-C16-OH. A di-lysine spacer, to mimic the 
spacing observed in the Lipid-Core Peptide (LCP) system, was then attached using 
two copies of Fmoc-Lys(Boc)-OH. The resin was then split into two 0.2 mmol 
batches. The DCpep (2; FYPSYHSTPQRP) or CONTROLpep (3; EPIHPETTFTNN) 
sequences were then attached using microwave assisted peptide synthesis, and 6-
maleimidohexanoic coupled to the N-terminus of each peptide using standard 
coupling conditions for 1 h at RT. The resins were subsequently washed with DMF × 
3, DCM × 3, dried overnight in a desiccator (under vacuum), and cleaved using 
95:2.5:2.5 TFA-triisopropylsilane-H2O (10 mL/g resin). Following removal of the 
cleavage cocktail using a high vacuum rotary evaporator at RT, the peptides were 
precipitated with ice-cold diethyl ether, pelleted by centrifugation (5 k ×g, 10 min, 
RT), dissolved in 40 % (v/v) aqueous MeCN containing 0.1 % (v/v) TFA, filtered, 
and lyophilized. The peptides were purified by RP-HPLC (60 % solvent B for 5 min, 




Peptide Analytical Data. 
Peptide 2. Yield: 43 %; HPLC: tR = 11.3 min (60-90 solvent B, C4), 25.7 min (0-100 
solvent B, C4); Purity: > 99 %; ESI-MS: m/z [M+2H]2+ 1402.3 (calcd. 1402.3), 
[M+3H]3+ 935.2 (calcd. 935.2), [M+4H]4+ 701.6 (calcd. 701.7), m/z 2802.8 
(reconstructed); MW 2802.5 g/mol. 
 
Peptide 3. Yield: 38 %; HPLC: tR = 14.8 min (60-90 solvent B, C4), 26.9 min (0-100 
solvent B, C4); Purity: > 99 %; ESI-MS: m/z [M+2H]2+ 1362.7 (calcd. 1362.2), 
[M+3H]3+ 908.5 (calcd. 908.5), m/z 2723.4 (reconstructed); MW 2722.4 g/mol. 
 
PCR-based Gene Synthesis7 to Generate GAS Polytope Gene. The polytope 
protein sequence (Table S1) was designed to incorporate: 1) a thrombin cleavable N-
terminal hexahistidine tag, 2) seven GAS M protein N-terminal peptide sequences,8 3) 
a sequence from the conserved C-terminal GAS M protein segment (p145, 
underlined) fused with yeast GCN4 sequences to promote helicity (yielding the J14 
peptide),9 and 4) a PADRE1024.03 universal T-helper epitope10 (sequences in Table 
S1). A di-lysine spacer was used to separate each component. The sequence was 
reverse translated and codon optimized for E. coli using the DNAworks server 
(http://helixweb.nih.gov/dnaworks/), followed by the manual addition of restriction 
sites (5’-NdeI and 3’-SapI) (Table S2; as described in the NEB Impact Kit manual) to 
allow for restriction/ligation cloning into pTXB1 (NEB). Overlapping 
oligonucleotides (Table S3) for PCR-based gene synthesis (≤ 60 bp length) were 
designed using assembly PCR oligomaker 
(http://publish.yorku.ca/~pjohnson/Assembly PCRoligomaker.html), and ordered 
from IDT with standard desalting. The oligonucleotides were individually dissolved 
in PCR grade water to 100 µM, and used to produce an internal oligonucleotide stock 
solution (F2-9 & R1-8; 5 µM/oligonucleotide). 
 
The PCR-based gene synthesis reaction was assembled using 10× KOD polymerase 
buffer #1 (5 µL; 1×), 2 mM dNTPs (5 µL; 0.2 mM), 25 mM MgCl2 (3 µL; 1.5 mM), 5 
µM internal oliognucleotide stock (0.2 µL; 20 nM/oligonucleotide), 100 µM external 
(F1 & R9) oligonucleotides (0.2 µL; 0.4 µM/oligonucleotide), and water to 50 µL. 
KOD DNA polymerase (2.5 U/µL; 0.4 µL; 1 U) was added. The reaction was 
denatured at 98 °C (15 sec), and then subjected to 25 cycles of 98 °C (15 sec), 50 °C 
(2 sec), and 72 °C (20 sec). The PCR product was purified using a QIAquick PCR 
purification kit, and eluted with water. 
 
Restriction-Free Cloning to Generate pTXB1_GAS polytope_GyrA Vector. The 
GAS polytope gene was inserted into pTXB1 using a restriction-free overlap 
extension PCR approach as described.11 Chimeric PCR primers (Table S2; RF series) 
were designed with 5’-ends that can anneal to the pTXB1 plasmid (Table S2; 
underlined) and 3’-ends that can anneal to the GAS polytope gene. The GAS polytope 
gene synthesis product was amplified by PCR using these primers and Phusion DNA 
polymerase to generate a linear product (a megaprimer) containing sequences from 
the pTXB1 plasmid at either end (Table S2). This product was gel purified and used 
in a second PCR reaction (10 µL volume; 18 cycles; 5 ng of pTXB1, 67 ng 
megaprimer (250 eq), Phusion DNA polymerase, and 3 % (v/v) DMSO) to 
incorporate the insert into the vector. Subsequently DpnI (0.5 µL; 20 U/µL; 10 U) was 
added to the reaction mixture, and incubated at 37 °C for 1 hour to destroy the 
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parental plasmid. This mixture (5 µL) was used to transform 50 µL of ultra-competent 
(Inoue method) DH5α E. coli by heat shock. The plasmid (pTXB1_GAS 
polytope_GyrA) was purified using a QIAprep spin minikit and sequenced. 
 
Site-Directed Mutagenesis to Generate pTXB1_GAS polytope-Cys Vector. The 
pTXB1_GAS polytope-Cys vector was generated from pTXB1_GAS polytope_Gyr A 
using the QuikChange XL II site-directed mutagenesis kit according to the 
manufacturers instructions. Primers (Table S2, Stop-For and Stop-Rev) were designed 
using the QuikChange Primer Design program (www.genomics.agilent.com). These 
primers were designed to convert an ATC (Ile) codon (3’ to the pTXB1 Mxe GyrA 
intein N-terminal TGC (Cys) codon) to an amber stop codon (TAG). 
 
Expression of the GAS-Cys Polytope Protein 1. The pTXB1-polytope-Cys vector 
was transformed into competent BL21-codonplus (DE3)-RIL E. coli by heat shock, 
and grown to OD600 0.6 at 37 °C, 250 RPM in LB (Miller) broth containing 100 
µg/mL ampicillin and 34 µg/mL chloramphenicol. Protein expression was induced 
with 0.5 mM IPTG, and the cells incubated for 4 hours at 37 °C, 250 RPM. The cells 
were pelleted (5 k ×g, 15 min, 4 °C), and lysed in denaturing lysis buffer (6 M 
guanidine-Cl, 500 mM NaCl, 20 mM Tris pH 8, 20 mM imidazole, 5 mM β-
mercaptoethanol) by sonication (6 x 30 sec on, 2 min off) on ice. The mixture was 
cleared (30 k xg, 20 min, RT). The expressed protein was purified from the 
supernatant using Ni-NTA beads. After binding for 1 h at 4 °C the beads were 
thoroughly washed with wash buffer (500 mM NaCl, 20 mM Tris pH 8, 20 mM 
imidazole, 5 mM β-mercaptoethanol), and PBS. The protein was eluted with 500 mM 
imidazole in wash buffer, and purified by HPLC (20 % solvent B for 5 min, then 20-
50 % solvent B over 60 min) on a C18 preparative scale column. Pure fractions were 
combined, lyophilized, and characterized by reversed-phase HPLC and ESI-MS. 
 
Conjugation of GAS Polytope and Lipid Adjuvants. Bioconjugation reactions were 
performed in maleimide conjugation buffer (6 M guanidine-Cl, 50 mM NaPi pH 7.3, 
20 % (v/v) MeCN, 5 mM EDTA). Lipid adjuvant peptides 2 or 3 were dissolved in 
DMSO as a solubility enhancer (final concentration 4 % (v/v)). Alternatively DMF 
was used, however lower product yields were observed. Use of TCEP to maintain 
reduced cysteine thiols is discouraged due to reactivity with maleimide groups12, 13 in 
the lipid adjuvant peptides. The reaction was performed as described. Briefly, to 8 mg 
of GAS-Cys polytope protein 1 (327 nmol; ~ 80 µM; ~ 2 mg/mL) dissolved in 4 mL 
maleimide conjugation buffer was added ~ 4.2 mg (~ 4.7 eq; 1534 nmol; ~ 384 µM) 
of lipid adjuvant peptide 2 or 3 dissolved in DMSO (160 µL). The reaction was left to 
incubate at RT for 30 min and subsequently purified by HPLC (30 % solvent B for 5 
min, then 30-100 % solvent B over 60 min) on a preparative C4 column to yield 
lipoprotein vaccine constructs 4 or 5 respectively. These constructs were 
characterized by analytical RP-HPLC and ESI-MS. Construct 4 was subjected to 
peptide mass fingerprinting after endoproteinase AspN digestion to provide evidence 
of site-specific conjugation, and to ensure the GAS-Cys polytope sequence is correct. 
 
Thrombin Cleavage of the N-terminal Hexahistidine-Tag. Lipoproteins 4 or 5 (4.6 
mg; ~168 nmol; ~ 1 mg/mL; ~ 37 µM) were dissolved in DPBS (4.5 mL) with bath 
ultrasonication. Thrombin (human plasma; 30 U) was added, and the reaction 
incubated at RT for 3 h. The product was subsequently purified by HPLC (30 % 
solvent B for 5 min, then 30-90 % solvent B over 60 min) on a preparative C4 column 
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to yield lipoprotein vaccine constructs 6 or 7 respectively. These constructs were 
characterized by analytical RP-HPLC, ESI-MS, DLS, and TEM. 
 
Protein Analytical Data. ESI-MS and RP-HPLC data for proteins is presented in 
Figure S1-S3. SDS-PAGE data is presented in Figure S4. 
 
GAS-Cys Polytope Protein (1). HPLC: tR = 18.0 min (0-70 % solvent B, C18), 16.8 
min (20-50 % solvent B, C18), 12.9 min (0-100 % solvent B, C4); Purity: > 99 %; 
ESI-MS: m/z 24,504.4 (reconstructed); MW 24,498.9*. 
 
Lipoprotein 4. Yield 71 %; HPLC: tR = 16.4 min (30-90 % solvent B, C4), 20.7 min 
(0-100 % solvent B, C4); Purity: > 99.5 %; ESI-MS: m/z 27,300.0 (reconstructed); 
MW 27,301.4*. 
 
Lipoprotein 5. Yield 89 %; HPLC: tR = 16.5 min (30-90 % solvent B, C4), 20.7 min 
(0-100 % solvent B, C4); Purity: > 99.5 %; ESI-MS: m/z 27,219.9 (reconstructed); 
MW 27,221.3*. 
 
* These constructs also contain a small amount of product missing the N-terminal 
alanine residue. This is due to cleavage of the initiator methionine by methionine 
aminopeptidase (MAP) followed by cleavage of the N-terminal alanine by MAP14 or 
another enzyme (e.g. PepN15). 
 
Lipoprotein (ΔHis6) 6. Yield 89 %; HPLC: tR = 17.8 min (30-90 % solvent B, C4), 
21.7 min (0-100 % solvent B, C4); Purity: > 99 %; ESI-MS: m/z 25,311.3 
(reconstructed); MW 25,313.4. 
  
Lipoprotein (ΔHis6) 7. Yield 75 %; HPLC: tR = 17.9 min (30-90 % solvent B, C4), 
21.7 min (0-100 % solvent B, C4); Purity: > 99 %; ESI-MS: m/z 25,239.0 
(reconstructed); MW 25,241.2. 
 
Evidence for Site-Specific Maleimide Conjugation Reactions, and Peptide Mass 
Fingerprinting (PMF) of the GAS-Cys Polytope Sequence. To confirm that the 
conjugation reaction between lipid adjuvant peptide 2 or 3 and the GAS-Cys polytope 
1 was site-specific, occurring only through the C-terminal cysteine residue, a PMF 
approach was taken. The enzyme endoproteinase Asp-N (cleaves N-terminally to Asp 
and cysteic acid) was selected, as it will not cleave within the lipid adjuvant peptide 2 
sequence. The proteolytic species generated will therefore contain peptides 
incorporating fragments of protein 1 conjugated to 2, which can be used to determine 
the conjugation site. Lipoprotein 4 (0.2 mg; ~7.3 nmol) was dissolved in 100 mM Tris 
pH 8 to 1 mg/mL (~ 36 µM) with bath ultrasonication. To this mixture was added 2 
µL endoproteinase Asp-N (80 ng; 40 µg/mL in 10 mM Tris-Cl pH 8; 1/2500 (w/w) 
enzyme to substrate ratio). The mixture was incubated at 37 °C for 18 hours and 
subsequently analysed by analytical RP-HPLC (0-100 % solvent B, C4; Figure S5, A) 
and LC-MS. All peaks were also subjected to offline ESI-MS analysis (to assign RP-
HPLC chromatogram peaks) and mapped against a table of endoproteinase Asp-N 
cleavage products generated by PeptideCutter 
(http://www.expasy.org/peptide_cutter/). This analysis yielded 79.8 % coverage of the 
lipoprotein 4 sequence (see Figure S5, C). Information relating to the hydrophobicity 
of the proteolyzed peptides, obtained from the RP-HPLC chromatogram, was used to 
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investigate whether the maleimide conjugation reaction was site-specific. The lipid 
adjuvant peptide 2 is extremely hydrophobic, eluting at 25.7 min (0-100 % solvent B, 
C4). In comparison, lipoprotein 4 eluted at 20.7 min, and GAS-Cys polytope protein 1 
eluted at 12.9 min. Based on this information, it would be expected that proteolytic 
peptides conjugated to lipid adjuvant 2 would elute after 20.7 min, since these 
peptides are significantly smaller than the full-length lipoprotein 4, and thus would 
not be expected to reduce the hydrophobic nature of 2 to the same extent as 1. Only 
one significant species was identified that eluted in this range (Peak L, 2.4 min in 
Figure S5, A). The mass of this species (whole peak; Figure S5, B) corresponded to 
the C-terminal Asp-N fragment (Figure S5, C; peak L) conjugated to 2, strongly 
supporting that conjugation occurred specifically through the C-terminal cysteine 
residue. 
 
Stock Solutions for Immunization. Lipoproteins 6 or 7, and protein 1 were 
dissolved in 6 M Gdn-Cl, 0.1 M NaPi pH 7.5 and quantified by measuring A280 
values, using extinction coefficients (1: 9970 M-1 cm-1; 6: 12950 M-1 cm-1; 7: 9970 M-
1 cm-1) calculated by ExPASy ProtParam (http://www.expasy.org/protparam). Known 
amounts of each compound were analyzed by RP-HPLC (0-100 % solvent B, C4), 
and used to define the amount of protein per area under the curve (AUC) unit at 214 
nm. This information was used to generate 0.6 mg/mL stock solutions of lipopeptide 6 
or 7, and a 1.2 mg/mL stock solution of protein 1 in 1× DPBS (Gibco). 
 
Endotoxin Testing. A Pyrochrome chromogenic Limulus amebocyte lysate (LAL) 
endpoint assay (Associates of Cape Cod, East Falmouth, MA, USA) was performed to 
certify that endotoxin levels for lipoprotein 6 and 7 stock solutions were below 
pharmacopoeia limits (USP/BP). The endotoxin limit (EL) concentration was set at 
1.2 IU/mL. This value was calculated using a minimal pyrogenic dose (K) of 0.06 
IU/dose, and an administered volume per dose of 50 µL. The K value was calculated 
using a 5 IU/kg endotoxin limit for parenteral administration (USP/BP) and a 12 g 
minimal mass for 4-6 week old female mice (source: Jax mice). All consumables 
were certified endotoxin free. Assays were performed in 96-well polystyrene plates 
with lids, using 50 µL total sample volumes. All samples were tested to ensure their 
pH was 6-8 and that they do not absorb at 400-410 nm. The following groups were 
assessed: 1) LAL reagent water and PBS (negative controls), 2) control standard 
endotoxin standard curve (0.1-2 IU/mL), 3) lipoproteins 6 and 7 (experimental 
group), 4) positive lipoprotein control (lipoproteins 6 and 7 spiked with control 
standard endotoxin to 0.5 IU/mL). The positive lipoprotein control groups were 
performed to ensure that lipoproteins 6 or 7 do not inhibit/enhance the amount of 
endotoxin detected. The Pyrochrome LAL reagent was reconstituted with Glucashield 
buffer, which prevents (1,3)-β-D-glucan contamination from activating the LAL 
cascade, leading to false positive results. Reconstituted Pyrochrome LAL reagent was 
added to each sample (50 µL/well), and the reaction incubated at 37 °C until all the 
standard curve sample samples displayed a yellow color. At this point reactions were 
stopped with 50 % (v/v) acetic acid-H2O (25 µL/well), and the OD405 value for each 
well was acquired using a microplate reader. Endotoxin levels were determined by 
comparison to the standard curve (OD405 against standard endotoxin concentrations). 
 
Immunization and Blood Collection. Immunization was performed under protocols 
approved by the Griffith University (BDD/06/10/AEC) and University of Queensland 
(SCMB/GRIFITH/005/12/MERCK/NIH/NHF/NHMRC) animal ethics committees in 
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accordance with Australian National Health and Medical Research Council 
(NHMRC) guidelines. Proteins (1, 6, and 7) were produced as 0.6 mg/mL stock 
solutions. Lipoproteins 6 and 7 were administered in 1× DPBS, and protein 1 as a 1:1 
emulsion with complete Freund’s adjuvant (CFA; positive control). C57BL/6J mice 
(♀; 5 weeks old; 5/group; Animal Resources Centre, WA, Australia) were immunized 
subcutaneously at the tail base with 30 µg (50 µL) of each stock solution, or with 50 
µL 1× DPBS (negative control), on days 0, 21, 28, and 35. On day 42, blood was 
collected from the tail vein, and left to clot for 1 h at 37 °C. Serum was collected after 
centrifugation (1000 ×g, 10 min, RT) and stored at -20 °C. 
 
Enzyme-Linked Immunosorbent Assay (ELISA). ELISA was performed 
essentially as described, using sera from individual mice.9 Peptide antigen stock 
solutions (5 µg/mL) were made in carbonate coating buffer (66 mM 
bicarbonate/carbonate pH 9.6) and used to coat polyvinylchloride (PVC) 96-well 
microtiter plates (100 µL/well; 0.5 µg/well) at 4 °C for 16 hours. The antigen 
solutions were then removed, and the wells blocked with 5 % (w/v) skim milk in 
PBS-T (0.05 % (v/v) tween-20, PBS) (150 µL/well) at 37 °C for 1.5 h. The plates 
were thoroughly washed (3× ddH2O, 2× PBS-T), and twofold serial dilutions of sera 
in 0.5 % (w/v) skim milk in PBS-T (starting at 1:100; 100 µL/well) produced. The 
plates were incubated at 37 °C for 1.5 h, washed (3× ddH2O, 2× PBS-T), and 
incubated at 37 °C for 1.5 h with α-mouse IgG-HRP conjugate (1:3000 dilution in 0.5 
% (w/v) skim milk in PBS-T; 100 µL/well). The plates were washed (3× ddH2O, 2× 
PBS-T), O-phenylenediamine (OPD; SIGMAFAST™ OPD; 100 µL/well) added, and 
incubated for 30 min in the dark at RT. Optical density was read at 450 nm using a 
microplate reader. Antibody titers were defined as the lowest dilution with an OD450 
value greater than three standard deviations above the mean absorbance of control 
wells (sera from PBS immunized mice).  
 
Statistics. Statistical comparison of antibody titers between groups was performed 
using a one-way analysis of variance (ANOVA) followed by a Tukey’s multiple 
comparison post-hoc test. Mean and standard error of the mean (SEM; σ/√n) were 
calculated using standard formula. GraphPad Prism 4 was used for statistical analysis, 
with P < 0.05 considered to be significant. 
 
Confocal Microscopy. Confocal microscopy was used to assess the capacity of 
murine antibodies elicited against 1 (primed with CFA) or 6 (administered in PBS) to 
bind cell surface M proteins from GAS serotypes represented by N-terminal M 
protein peptides included in our polytope constructs (88/30 (emm97), PL1 (emm54), 
NS1 (emm100), Y504S (emm11), BSA10 (emm2.3), NS27 (emm91), NS5 
(emm101))16, or against pM1 (emm1),17 which contains the conserved M protein 
J14i18 epitope found in J14. The confocal microscope was calibrated for positive and 
negative samples using pM1 GAS and murine antisera raised against recombinant M1 
protein (primed with CFA)19 as a positive control, or antisera from sham (PBS) 
immunized mice as a negative control. Murine antisera against recombinant arginine 
deiminase (ADI)19 (99 % conserved amongst serotypes) was used as an additional 
positive control for each strain. 
 
Slides were prepared as described.20 A colony of each GAS strain was grown 
overnight at 37 °C (without shaking) in Todd Hewitt broth (5 mL) supplemented with 
1 % yeast extract (THBY) and 28 µm E-64 (to inhibit M protein proteolysis by SpeB). 
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The cultures were subsequently pelleted (3 k ×g, 5 min, RT), washed (2 × PBS), and 
resuspended to OD600 ~ 0.4 in PBS. Each suspension (10 µL) was dispensed into wax 
circles (~ 1.2 cm ⌀;	  ImmEdge	  pen,	  Vector	  Laboratories,	  USA)	  on	  polylysine	  slides	  
(Erie Scientific, USA), spread, and left to air dry. Bacteria were fixed with 3 % (w/v) 
paraformaldehyde-PBS (10 min), washed (PBS, 10 min), and blocked with 3 % (w/v) 
bovine serum albumin (BSA)-PBS-T (150 µL/sample, 37 °C, 30 min). For all 
subsequent steps, antibodies were diluted with 0.3 % (w/v) BSA-PBS. The slides 
were washed (PBS, 2 × 10 min), and GAS cell surface immunoglobulin binding sites 
blocked with a 1:200 dilution of human plasma IgG (10 mg/mL stock; Calbiochem; 
150 µL/sample, 37 °C, 1 h). After washing (PBS, 2 × 10 min), the slides were treated 
with a 1:200 dilution of pooled murine antiserum (final bleed; 150 µL/sample, 37 °C, 
1.5 h) from protein 1 (primed with CFA), lipoprotein 6 (1:50 dilution for Y504S and 
pM1), sham (PBS), recombinant M1 GAS M protein (primed with CFA), or 
recombinant ADI (primed with CFA) immunized mice. The slides were washed (PBS, 
3 × 10 min) and incubated with a 1:200 dilution of FITC-labeled secondary antibody 
(goat anti-mouse IgG-FITC conjugate, Zymed, USA; 150 µL/sample, 4 °C, 
overnight). After washing (PBS, 3 × 10 min), Vectashield Hardset mounting medium 
(7.5 µL/sample; Vector Laboratories, USA) was applied to adhere glass coverslips. 
Confocal images were acquired using a Plan-Apochromat 100×/1.40 oil immersion 
DIC objective lens and Argon/2 laser with excitation at 488 nm for FITC. Filter sets 
were configured for detection of FITC. Brightfield DIC images were acquired to 




Table S1. The sequence of the designed polytope protein, each of the GAS M protein 














GAS M protein Conserved Peptide Epitopes 
J14 KQAEDKVKASREAKKQVEKALEQLEDKVK 
GAS M Protein N-terminal Peptide Epitopes 
88/301-20 (emm97) DNGKAIYERARERALQELGP 
PL11-19 (emm54) EVLTRRQSQDPKYVTQRIS 
NS11-19 (emm100) RVTTRSQAQDAAGLKEKAD 
Y504S1-20 (emm11) TEVKAAGQSAPKGTNVSADL 
BSA101-28 (emm2.3) NSKTPAPAPAVPVKKEATKSKLSEAELH 
NS271-19 (emm91) ADDHPGAVAARNDVLSGFS 
NS51-19  (emm101) ADHPSYTAAKDEVLSHFSV 





Table S2. The sequence of a) the codon-optimized polytope gene, with 5’-NdeI and 
3’-SapI restriction sequences added (underlined), b) the polytope megaprimer 
(underlined portions anneal to pTXB1 vector), and c) 
































Table S3. Primers for PCR-based gene synthesis (F and R series) of the GAS 
polytope, restriction-free cloning (RF series; underlined portion anneals to vector), 
and generation of C-terminal cysteine by site-directed mutagenesis (Stop series; stop 
codon in bold). 




























Figure S1. ESI-MS and RP-HPLC data for (A) polytope protein 1, (B) lipid adjuvant 
2, and (C) lipid adjuvant 3. 
  




























Figure S4. SDS-PAGE (4-12 % Biorad Mini-PROTEAN TGX) of protein products, 





















Figure S5. Peptide mass fingerprinting data (ESI-MS and RP-HPLC) for lipoprotein 4 
after digestion with endoproteinase Asp-N. (A) RP-HPLC chromatogram of Asp-N 
digest reaction. (B) ESI-MS data for peak L (22.4 min) corresponding to the C-
terminal polytope Asp-N digest peptide conjugated to peptide 2. (C) Table of 
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A* 6.4 SSRVHHHHHHGSGLVPRGKKKQAE 2707.0 [M+3H]3+ 904.2, [M+4H]4+ 678.1, [M+5H]5+ 543.0 
B 10.9 DKVKASREAKKQVEKALEQLE 2427.8 [M+2H]2+ 1215.2, [M+3H]3+ 810.7, [M+4H]4+ 608.8 
C - DKVKKK 744.9 Not identified 
D - DNGKAIYERARERALQELGPKKEVLTRRQSQ 3641.1 Not identified 
E 7.7 DPKYVTQRISKKRVTTRSQAQ 2490.8 [M+2H]2+ 1246.9, [M+3H]3+ 624.2 
F 5.8 DAAGLKEKA 902.0 [M+H]+ 903.3 
G 6.6 DKKTEVKAAGQSAPKGTNVSA 2087.3 [M+2H]2+ 1044.6, [M+3H]3+ 696.9 




I 5.6 DDHPGAVAARN 1122.2 [M+H]+ 1123.1, [M+2H]2+ 1123.1 
J 9.2 DVLSGFSKKA 1051.2 [M+H]+ 1052.5, [M+2H]2+ 527.3 























Figure S6. Assessment	   of	   antigen-­‐mediated	   immunity	   elicited	   in	   response	   to	  
immunization	   with	   recombinant	   antigen	   1	   (primed	   with	   CFA),	   lipoprotein	   6	  
(includes	  DCpep)	  or	  7	  (includes	  CONTROLpep),	  or	  PBS	  sham	  (negative	  control).	  
An	   ELISA	  was	   used	   to	  measure	   the	  mean	   antigen-­‐specific	   serum	   IgG	   antibody	  
titers	  (log10),	  against	   the	  eight	  polytope	  antigens,	   from	  sera	  collected	  one-­‐week	  
after	   the	   final	   boost.	   Plates	   were	   coated	   with	   synthetic	   peptide	   antigens.	   The	  
capacity	  for	  antibodies	  against	  J14	  to	  bind	  the	  folded	  J14i	  conformational	  epitope	  
was	   demonstrated	   using	   p145.	   Data	   is	   represented	   as	   scatterplots	   for	   each	  
antigen	  group	  (n	  =	  5),	  with	  mice	  that	  did	  not	  respond	  to	  immunization	  indicated	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